Track topics on Twitter Track topics that are important to you
GenSight Biologics has reported that GS010, an intravitreal injection treatment for Leber’s hereditary optic neuropathy, has shown positive long-term visual acuity and safety results after 96 weeks, according to a company press release.In the phase 1/2 trial, a single intravitreal injection of GS010 was administered in the eye most severely affected by the disease.NEXT ARTICLE
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...